Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN. Sharman JP, Egyed M, Jurczak W, Skarbnik A, et al. Blood 2025;146:1276-1285.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sharman JP, Egyed M, Jurczak W, Skarbnik A, et al. Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN. Blood 2025;146:1276-1285.
PMID: 40198878